Tuesday, October 23, 2018
- 9:00AM-11:00AM
-
Abstract Number: 2727
Prevalence of Clinical and Subclinical Ophthalmologic Manifestations in Association with Systemic Symptoms, Disease Activity and Damage in Patients with Granulomatosis with Polyangiitis
Vasculitis – ANCA-Associated Poster II- 9:00AM-11:00AM
-
Abstract Number: 2232
Prevalence of Gout in the Surviving U.S. Solid Organ Transplant Population
Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II- 9:00AM-11:00AM
-
Abstract Number: 2131
Prevalence of Systemic Lupus Erythematosus (SLE) and Associated Comorbidities in the 2011-2015 Medicare Population
Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases- 9:00AM-11:00AM
-
Abstract Number: 2237
Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)
Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II- 9:00AM-11:00AM
-
Abstract Number: 2137
Primary Antiphospholipid Syndrome with Vascular Manifestations Is a Rare Disease: A Population-Based, Multi-Source Study Assessing the Prevalence and Incidence in Adults
Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases- 9:00AM-11:00AM
-
Abstract Number: 2570
Probability of Achieving Low Disease Activity or Remission in Subjects with Active Psa Treated with Apremilast
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment- 9:00AM-11:00AM
-
Abstract Number: 2186
Process Evaluation of a Culturally-Sensitive, Community Based Self-Management Program for First Nations People with Arthritis and Their Families
Health Services Research Poster III – ACR/ARHP- 9:00AM-11:00AM
-
Abstract Number: 2695
Progressive Skin Fibrosis, Internal Organ Involvement and All-Cause Mortality in an Early Diffuse Cutaneous Systemic Sclerosis United States Multicenter Registry
Systemic Sclerosis and Related Disorders – Clinical Poster III- 9:00AM-11:00AM
-
Abstract Number: 2466
Prolonged Delay in Presentation to Rheumatologists for Hispanic Patients with Rheumatoid Arthritis Contributes to Later Diagnosis and Treatment
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2617
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment- 9:00AM-11:00AM
-
Abstract Number: 2475
Promis Pain Interference 6b and Fatigue 7a Short Forms and Profile-29 in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2481
Proposal to Re-Evaluate the Definition of Low Disease Activity in Routine Assesment of Patient Index Data 3 (RAPID3) in Rheumatoid Arthritis Patients
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2450
Prosthetic Joint Infection in Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2223
Proton Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition (CPPD) in a Population-Based Study